Benoxinate
Active ingredient: Benoxinate Hydrochloride
In short: Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.
What is Benoxinate used for?
Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is indicated for ophthalmic procedures in adult and pediatric patients requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.
Benoxinate dosage
Instill 1 to 2 drops topically in the eye as needed.
How to take Benoxinate — instructions & advice from the label
Accidental Injury Precaution
Advise patients not to touch their eyes for approximately 20 minutes after application. Their eyes will be insensitive due to the effect of the anesthetic, and care should be taken to avoid accidental injuries.
Distributed by:
Bausch & Lomb Americas Inc.
Bridgewater, NJ 08807 USA
Manufactured by:
Siegfried-Irvine
Irvine, CA 92618 USA
Patented. See
https://patents.bausch.comfor US patent information.
© 2022 Bausch & Lomb Incorporated or its affiliates
9785500
Warnings & precautions
Do not take this medicine if: Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is contraindicated in patients with known hypersensitivity to any component of this product.
Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage with accompanying visual loss.
Patients should not touch the eye for approximately 20 minutes after using this anesthetic as accidental injuries can occur due to insensitivity of the eye.
Benoxinate side effects
The following serious ocular adverse reactions are described elsewhere in the labeling:
Corneal Toxicity
Corneal Injury Due to Insensitivity
The following adverse reactions have been identified following use of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4%: ocular hyperemia, burning, stinging, eye irritation, blurred vision and punctate keratitis. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
About this medicine
Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, 0.3%/0.4% is a sterile solution containing a disclosing agent in combination with a short-acting ester anesthetic for topical ophthalmic use.
Fluorescein sodium is represented by the following structural formula:
Chemical Name: 3’,6’ Dihydroxy-3H-spiro[isobenzofuran-1,9-xanthen]-3-one disodium salt.
Benoxinate hydrochloride is represented by the following structural formula:
Chemical Name: 2-(Diethylamino) ethyl 4-amino-3-butoxybenzoate hydrochloride.
Each mL of Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution 0.3%/0.4% contains:
Active ingredients:fluorescein sodium 2.6 mg (0.3%) equivalent to fluorescein 2.3 mg (0.2%), benoxinate hydrochloride 4.4 mg (0.4%) equivalent to benoxinate 3.9 mg (0.4%)
Preservative:chlorobutanol 12.6 mg (1.3%)
Inactive ingredients:povidone, hydrochloric acid, boric acid, water for injection. Hydrochloric acid may be added to adjust pH (4.3 – 5.3). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1797c5ef-66c4-4cf8-b62d-b484242be2ee. Read the full official label on DailyMed.
Related medicines
Azithromycin Latanoprost Amoxicillin and Clavulanate Cephalexin Sulfamethoxazole and Trimethoprim Ofloxacin Timolol Cefdinir